Jacalyn Rosenblatt, MD
Enriched profileDeputy Director, Cancer Immunotherapy Institute, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School · Beth Israel Deaconess Medical Center
Jacalyn Rosenblatt is Deputy Director, Cancer Immunotherapy Institute, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School at Beth Israel Deaconess Medical Center. OpenAlex indexes 393 publications with 8,531 citations (h-index 43); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Jacalyn Rosenblatt, MD, is Deputy Director, Cancer Immunotherapy Institute, Beth Israel Deaconess Medical Center. The public record shows 393 publications with 8,531 citations (h-index 43), centered on Hematology. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 7 companies, 2 NIH-funded awards (2010–2026).
- Most recent indexed publication: 2026 · Cancer immunology research
- Top research focus: Hematology
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 7 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 2 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Sponsor: David Avigan
- Abatacept for Patients With COVID-19 and Respiratory Distress
Sponsor: Beth Israel Deaconess Medical Center
- Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
Sponsor: Beth Israel Deaconess Medical Center
Industry payments
Updated 14 Oct 2026
7 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year202411 payments$33,525openpaymentsdata.cms.gov ↗
- BeiGene, Ltd.Program year20241 payment
- Janssen Biotech, Inc.Program year20241 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
100%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor100%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
2 NIH research awards on record, funded 2010–2026 per NIH RePORTER. The latest:
- Personalized Adoptive T-cell Therapy for AML
Beth Israel Deaconess Medical Center
FY2026$728,501R01CA262629 - Personalized Adoptive T-cell Therapy for AML
Beth Israel Deaconess Medical Center
FY2025$728,501R01CA262629 - Personalized Adoptive T-cell Therapy for AML
Beth Israel Deaconess Medical Center
FY2024$692,077R01CA262629
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.
Cancer immunology research
Clinical Trial2026
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jacalyn-rosenblatt-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/jacalyn-rosenblatt-8b822456
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/BIDMC/posts/jacalyn-rosenblatt-md-deputy-director-of-the-cancer-immunotherapy-institute-at-b/10160524683190137
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - X / Twitter
x.com/BIDMC_CancerCtr/status/2011105964125274450
- YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - X / Twitter
BIDMC Cancer Center (X/Twitter) post on research team led by David Avigan, MD, and Jacalyn Rosenblatt, MD
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.usnews.com ↗
- Board Certified
Internal Medicine (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →everydayhealth.care ↗ - Board Certified
Hematology (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →everydayhealth.care ↗
Editorial & leadership roles
journal and society appointments- Deputy Director
Cancer Immunotherapy Institute, BIDMC
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newswise.com ↗ - Co-lead (with David Avigan, MD)
personalized dendritic cell/tumor fusion vaccine research program for hematologic malignancies
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →m.facebook.com ↗
Secondary affiliations
appointments beyond the home institution- Associate Professor of Medicine
Harvard Medical School
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dfhcc.harvard.edu ↗ - Medical Director
Schwartz Cancer Immunotherapy and Cell Manipulation Facility, BIDMC
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →newswise.com ↗ - Scholarship Advisor
Hematology-Oncology Fellowship Program, BIDMC
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bidmc.org ↗
Media & interviews
press, podcasts and appearances- YouTube: "CAR T-Cell Therapy and Vaccines in Multiple Myeloma"
2026 Multiple Myeloma Symposium presentation
2026provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Matcheri Keshavan, MD
Beth Israel Deaconess Medical Center
Connie Tsao, MD
Beth Israel Deaconess Medical Center
Donald Cutlip, MD
Beth Israel Deaconess Medical Center
Robert Yeh, MD
Beth Israel Deaconess Medical Center
Joseph Antin, MD
Boston University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center